XH 001
Alternative Names: XH-001Latest Information Update: 26 Feb 2026
At a glance
- Originator NeoCura
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gastric cancer; Gastrointestinal cancer
- Preclinical Pancreatic cancer
Most Recent Events
- 10 Feb 2026 Phase-I clinical trials in Gastrointestinal cancer (Combination therapy, Late-stage disease) in China (Parenteral) (NCT07329894)
- 09 Jan 2026 NeoCura in collaboration with Beijing GoBroad Hospital plans a phase I trial for Gastrointestinal-cancer (Late-stage disease, Combination therapy) in China (Injection) in January 2026 (NCT07329894)
- 29 Dec 2025 NeoCura plans a phase I trial in Gastric cancer (Late-stage disease, Combination therapy) (NCT07298200)